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458* The prognosis of cystic ﬁbrosis in the Western Cape province
of South Africa: a 33 year study
A.T. Westwood1. 1Division of Paediatric Medicine, University of Cape Town,
Cape Town, South Africa
Background: Cystic ﬁbrosis (CF) occurs in all population groups in South Africa,
a middle income country with signiﬁcant poverty levels.
Patients and Methods: Applying Kaplan–Meier statistics to a database of CF
patients in the Western Cape province, the overall survival of 217 patients with CF
was studied over a 33 year period (1974–2007). The effect of sex and ethnicity on
prognosis was explored.
Results: Median survival was 20.8 years (25th percentile: 11.6 years). There was
no signiﬁcant difference in survival between males and females (p = 0.5). There was
a signiﬁcant difference in prognosis between white (N = 116) and mixed ethnicity
(N = 92) patients (p = 0.0025). There were 17 deaths in infancy (22.6% of all deaths)
spread equally across the period. Infant deaths accounted for 2/33 deaths in white
patients versus 13/39 deaths in mixed ethnicity patients. Median survival beyond
infancy for white patients was 25.8 years versus 20.5 for mixed ethnicity patients
(p = 0.007). There was no demonstrable improvement in survival for patients born
in the second half of the study period.
Conclusions: Median survival is into adulthood in this population. Infant death due
to CF is a signiﬁcant risk in the province. There is an ethic difference in survival
that is likely to relate to awareness of CF in different populations and differences
in socio-economic status.
459 The characteristic of children with cystic ﬁbrosis from Moldova
according to European Registry criteria
S. Sciuca1, E. Chioroglo1, O. Turcu1, A. Jivalcovschi1, V. Egorov1. 1Pediatry,
State Medical and Pharmaceutical University, Chisinau, Moldova
Aim: To analyze the information about children with cystic ﬁbrosis (CF) from
Moldova according to European Registry of CF.
Materials and Methods: This study included 55 children (32 boys, 23 girls at
the mean age of 9.67±0.9). Genetic diagnosis was realized in all the children
and their parents for 4−7 CFTR mutations. The explorative program for children
with CF according to European Registry includes: sweat test, spirography, sputum
bacteriology, body mass index and pancreatic status appreciation.
Results: The diagnostic of CF was established at the mean age of 3.71±0.7. In
25 children (44.6%) DF508 mutation was revealed (12 children homozygote, 13
heterozygote), L551D mutation – 1 child, R334W – 1 case, G542X/N103K –
1 child. Sweet test value consists 92.9±4.6mmol/l. Bacteriology of sputum was
characterized by prevalence of pulmonary infection with S. aureus in 48.25%,
Ps.aeruginosa – 30.35%. The respiratory pulmonary function was characterized
by restrictive and obstructive impairments FVC –61.5±3.6%, FEV1 – 64.5%.
Nutritional disorders were determined in 87.5% characterized by low BMI
(15.95±0.3 kg/m2). Pancreatic insufﬁciency was revealed in 78.6% cases. There
are 5 children ofﬁcial registered died from CF during last 5 years (2 children at the
age of 1 year, 2 at 2−3 years, 1 child at 17 years). The cause of death in all cases
was infectious pulmonary complications.
Conclusion: In children evaluated according to European Registry of CF criteria
high incidence of DF508 mutation, the presence of pulmonary disorders and in 1/3
of children chronic colonization of low airways with Ps. aeruginosa were observed.
The implication of gastrointestinal system characterized by pancreatic insufﬁciency
and impaired nutrition was present in most of children.
460 Data from the Croatian CF Registry
D. T-Drinkovic1, D. Tjesic-D1, J. Kelecic1, A. Votava1. 1Dept. of Pediatrics,
University Hospital Centre, Zagreb, Croatia
In 2007 Croatia joined the European CF Registry and parallely, following the same
instructions for data collection, the national CF registry was started. We present the
ﬁrst data on our CF patients.
Croatia has about 4.500000 inhabitants and a total of 108 CF patients are reported
(52.8% male). 52% are followed at the University Hospital Centre Zagreb and the
rest are distributed among 5 other institutions. We have no neonatal screening.
Median age at diagnosis is 5 mo, with 46.6% patients identiﬁed by the 3rd mo of
life. The median age of our patients is 14.5 y and the oldest has 28 y. The range of
sweat chloride concentration is 43–280mmol/l. Most patients have 90–120mmol/l
(59.9%); the median concentration is 105mmol/l. The most frequent CFTR muta-
tion is dF508 (78.2% of all identiﬁed mutations). 61 patient is homozygous and 36
patients are heterozygous for dF508. Other mutations found are G542X, R117H,
N1303K, and 1717−1G-A. 3 patients have no identiﬁed mutation (N/N) and 32
patients have one unknown mutation (15.5%). Most patients are PI (96.3%). 20 had
meconium ileus. The overall nutritional status of our patients is fairly good with
the medium BMI %tile of 45, but 33.8% have BMI bellow 25% tile. We have 4
patients with CFRD. In 2006/07 Pseudomonas aeruginosa was isolated in 46% of
patients and Burkholderia cepacia in 2 patients. We treated 3 patients for ABPA.
No patients have liver or lung transplant.
Comment: Only 108 patients registered among the Croatian population with the
genotype similar to surrounding nations means CF is underdiagnosed. However,
the care for patients is fairly good with acceptable ﬁgures regarding bacteriological
isolations, nutritional status, age at diagnosis and actual patients age.
Acknowledgements for data: I. Golmajer, S. Banac, D. Richter, S. Dragisic,
E. Verona.
461 CF Registry in Slovakia
H. Kayserova´1, A. Feketeova´3, B. Taka´cˇ2, I. Mikula´sˇova´1, B. Remisˇ1,
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Bratislava, Slovakia; 2CCF, Children’s Clinic, Banska´ Bystrica, Slovakia; 3CCF,
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Slovak CF Registry was established in 1995 and includes 505 CF patients in the
end of 2006, 251 males, 254 females, mean age 18.9 years. 106 pts. died in this
period with increasing mean age from 3.4 years in 1974–1980 to 16.3 years in
2000–2006. There are 187 adults (46.9%), 212 children (53.1%), 9 patients are
older thane 60 year. 93.4% of the patients are genetically evaluated, the prevalence
of dF508 being 46.35%. Nevertheles, 33.4% of our patients who where tested, have
unknown mutation. Data on registry are obtained from 3 CF centres and includes
demographic data (sex, date of birth and death, genotyping, social status), sweat
chloride, age in diagnosis, clinical symptoms, pancraetis status). We do out-patient
visits every 1−3 months (spirometry, anthropometric measurements, blood samples
for hematology, biochemistry and immunology and sputum collection). Data of
therapy: antibiotics, mucolytics, antiinﬂammatory therapy, ursodeoxycholic acid,
pancretic enzymes, enteric suplements, lung and liver transplantion.
Results: See the table.
Clinical symptoms and therapy in CF patients
Mean FVC 85.3% DIOS 8.0% rhDNA 38.6%
Mean FEV1 85.0% MI 8.4% PET 72.3%
Colonisation Prolaps 7.1% UDCA 41.7%
Pseudomonas spp. 42.9% Sinusitis 59.3% Supplements 41.8%
Burkholderia spp. 14.6% Polyposis 21.4% CS 10.7%
PI 65.9% ABPA 10.0% ICS 23.3%
CPI 11.4% IGT 37.0% AZI 30.7%
CFRLD 48.6% CFRDM 5.7% Lung Tx 4 pts
Cirrhosis 6.3% Inhaled antibiotics 36.6% Liver Tx 0
